RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Realcan Pharmaceutical Group Co Stock

Realcan Pharmaceutical Group Co Equity 2024

Realcan Pharmaceutical Group Co Equity

5.45 B CNY

Ticker

002589.SZ

ISIN

CNE1000013X5

In 2024, Realcan Pharmaceutical Group Co's equity was 5.45 B CNY, a 0.75% increase from the 5.41 B CNY equity in the previous year.

Realcan Pharmaceutical Group Co Aktienanalyse

What does Realcan Pharmaceutical Group Co do?

Realcan Pharmaceutical Group Co. Ltd is a Chinese pharmaceutical company based in the city of Chengdu. The company was founded in 2009 and has since built a deep knowledge and understanding of the pharmaceutical industry in the Chinese market. Since its inception, the company has developed a wide range of drugs and health products. Realcan Pharmaceutical Group Co. Ltd has established itself as one of the largest and most reliable pharmaceutical companies in China, specializing in the development, manufacturing, and marketing of pharmaceuticals. The business model of Realcan Pharmaceutical Group Co. Ltd is based on a variety of growth drivers, including entering new markets and developing new products. The company has always focused on leveraging the experience and expertise of its employees to deliver innovations and high-quality products that have a positive impact on consumer health. The company places the highest value on the quality, safety, and effectiveness of its products and services. Realcan Pharmaceutical Group Co. Ltd offers a wide range of products, ranging from drugs and medications to health products and supplements. The company specializes in various areas, including oncology, dermatology, cardiology, neurology, respiratory diseases, gastroenterology, and endocrinology. Several products from Realcan have already received approval from the Chinese health authority and are available on the market. Some of the company's most well-known products include the anti-tumor drugs Nifuratel and Nifuratrone, the cardiology product Cardio Protect, and the neurology product Neuro Relief. Realcan Pharmaceutical Group Co. Ltd also specializes in the production of traditional Chinese medicine and herbal medicine. Traditional Chinese medicine is gaining increasing importance in the Chinese market as it is considered an effective alternative to Western medicine. Realcan Pharmaceutical Group Co. Ltd is committed to promoting research and development in the field of traditional Chinese medicine. The company works closely with universities and other research institutions to develop effective and safe herbal medicine. Realcan Pharmaceutical Group Co. Ltd also specializes in entering international markets. The company exports its products to various countries, including the United States, Australia, France, India, and Japan. The company places great emphasis on complying with international standards and ensuring the safety and quality of its products. In summary, Realcan Pharmaceutical Group Co. Ltd is an innovative Chinese pharmaceutical company that offers a wide range of pharmaceutical products and services. The company has established itself as a reliable brand in the field of drug development and manufacturing and is committed to adhering to global standards to strengthen customer trust. Realcan Pharmaceutical Group Co. Ltd will continue to play an important role in the Chinese and international markets and consolidate its leadership position as a reliable and innovative pharmaceutical company. Realcan Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Realcan Pharmaceutical Group Co's Equity

Realcan Pharmaceutical Group Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Realcan Pharmaceutical Group Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Realcan Pharmaceutical Group Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Realcan Pharmaceutical Group Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Realcan Pharmaceutical Group Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Realcan Pharmaceutical Group Co stock

What is the equity of Realcan Pharmaceutical Group Co this year?

Realcan Pharmaceutical Group Co has equity of 5.45 B CNY this year.

What was the equity of Realcan Pharmaceutical Group Co compared to the previous year?

The equity of Realcan Pharmaceutical Group Co has increased/decreased by 0.75% increased compared to the previous year.

What impact does a high equity have on investors of Realcan Pharmaceutical Group Co?

A high equity is advantageous for investors of Realcan Pharmaceutical Group Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Realcan Pharmaceutical Group Co?

A low equity can be a risk for investors of Realcan Pharmaceutical Group Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Realcan Pharmaceutical Group Co affect the company?

An increase in equity of Realcan Pharmaceutical Group Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Realcan Pharmaceutical Group Co affect the company?

A reduction in equity of Realcan Pharmaceutical Group Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Realcan Pharmaceutical Group Co?

Some factors that can affect the equity of Realcan Pharmaceutical Group Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Realcan Pharmaceutical Group Co so important for investors?

The equity of Realcan Pharmaceutical Group Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Realcan Pharmaceutical Group Co take to change the equity?

To change equity, Realcan Pharmaceutical Group Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Realcan Pharmaceutical Group Co pay?

Over the past 12 months, Realcan Pharmaceutical Group Co paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 0.31 %. For the coming 12 months, Realcan Pharmaceutical Group Co is expected to pay a dividend of 0.01 CNY.

What is the dividend yield of Realcan Pharmaceutical Group Co?

The current dividend yield of Realcan Pharmaceutical Group Co is 0.31 %.

When does Realcan Pharmaceutical Group Co pay dividends?

Realcan Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, August, July.

How secure is the dividend of Realcan Pharmaceutical Group Co?

Realcan Pharmaceutical Group Co paid dividends every year for the past 0 years.

What is the dividend of Realcan Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.01 CNY are expected. This corresponds to a dividend yield of 0.31 %.

In which sector is Realcan Pharmaceutical Group Co located?

Realcan Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Realcan Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Realcan Pharmaceutical Group Co from 6/4/2024 amounting to 0.013 CNY, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.

When did Realcan Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 6/4/2024.

What was the dividend of Realcan Pharmaceutical Group Co in the year 2023?

In the year 2023, Realcan Pharmaceutical Group Co distributed 0.018 CNY as dividends.

In which currency does Realcan Pharmaceutical Group Co pay out the dividend?

The dividends of Realcan Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Realcan Pharmaceutical Group Co

Our stock analysis for Realcan Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Realcan Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.